EGFR and non-small cell lung carcinoma: For instance, 50% of Asian patients and 10–15% of Caucasian patients with lung adenocarcinoma are EGFR mutation-positive, with 5% of NSCLC being ALK positive and 1% of NSCLC patients being ROS1 positive [138,139,140].